Our top pick for
Building a portfolio

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Agios Pharmaceuticals, Inc is a biotechnology business based in the US. Agios Pharmaceuticals shares (AGIO) are listed on the NASDAQ and all prices are listed in US Dollars. Agios Pharmaceuticals employs 562 staff and has a trailing 12-month revenue of around USD$203.2 million.
Our top pick for
Building a portfolio
Our top pick for
Beginners
Our top pick for
Active traders
52-week range | USD$32.47 - USD$58.93 |
---|---|
50-day moving average | USD$50.3718 |
200-day moving average | USD$44.7084 |
Wall St. target price | USD$64.89 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | USD$-6.673 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Revenue TTM | USD$203.2 million |
---|---|
Gross profit TTM | USD$-167,079,000 |
Return on assets TTM | -22.66% |
Return on equity TTM | -62.95% |
Profit margin | -161.11% |
Book value | $5.765 |
Market capitalisation | USD$3.7 billion |
TTM: trailing 12 months
There are currently 5.3 million Agios Pharmaceuticals shares held short by investors – that's known as Agios Pharmaceuticals's "short interest". This figure is 15.5% down from 6.3 million last month.
There are a few different ways that this level of interest in shorting Agios Pharmaceuticals shares can be evaluated.
Agios Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Agios Pharmaceuticals shares currently shorted divided by the average quantity of Agios Pharmaceuticals shares traded daily (recently around 839901.9047619). Agios Pharmaceuticals's SIR currently stands at 6.3. In other words for every 100,000 Agios Pharmaceuticals shares traded daily on the market, roughly 6300 shares are currently held short.
However Agios Pharmaceuticals's short interest can also be evaluated against the total number of Agios Pharmaceuticals shares, or, against the total number of tradable Agios Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Agios Pharmaceuticals's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 Agios Pharmaceuticals shares in existence, roughly 80 shares are currently held short) or 0.1136% of the tradable shares (for every 100,000 tradable Agios Pharmaceuticals shares, roughly 114 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Agios Pharmaceuticals.
Find out more about how you can short Agios Pharmaceuticals stock.
We're not expecting Agios Pharmaceuticals to pay a dividend over the next 12 months.
Over the last 12 months, Agios Pharmaceuticals's shares have ranged in value from as little as $32.47 up to $58.93. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Agios Pharmaceuticals's is 1.6442. This would suggest that Agios Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Agios Pharmaceuticals, Inc. , a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers TIBSOVO (ivosidenib), an oral targeted inhibitor for treating adult patients with relapsed or refractory acute myeloid leukemia (R/R AML), as well as to treat patients with newly diagnosed AML; and IDHIFA (enasidenib), an oral targeted inhibitor for patients with R/R AML and an isocitrate dehydrogenase 2 mutation. It is also developing TIBSOVO, which has completed Phase II clinical trials to treat IC eligible frontline AML; that is in Phase III clinical trials for treating IC ineligible frontline AML; and that is in Phase III clinical trials for the treatment of cholangiocarcinoma, as well as in early stage clinical development to treat glioma and solid tumors. In addition, the company is developing IDHIFA, which has completed Phase II clinical study for treating IC eligible frontline AML; and that is in Phase I/II clinical trials for the treatment of IC ineligible frontline AML. Further, it is developing mitapivat, which is in Phase III clinical trials to treat pyruvate kinase deficiency, as well as in Phase II clinical study for treating thalassemia and sickle cell disease; vorasidenib (AG-881) that is in Phase I clinical trials for the treatment of solid tumors, including glioma; AG-270, which is in Phase I dose-escalation trial to treat methylthioadenosine phosphorylase deleted tumors; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc.
Features, fees and complaints to consider before you apply for a T. Rowe Price account.
Steps to owning and managing ZTO, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZOM, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZI, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZKIN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZION, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZNTL, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZGYH, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZEAL, with 24-hour and historical pricing before you buy.
Steps to owning and managing CTIB, with 24-hour and historical pricing before you buy.